News/Press

An ‘open’ Molecular Diagnostic system which perfectly describes the Fast MDx platform, would be a “game-changer” in Low- and Middle-Income Countries (LMIC), according to a recent Belgium academic paper published in Expert Review of Molecular Diagnostics .

A new coalition of industry and health charities, led by former Health Minister, raise the alarm over missed opportunities to tackle Antimicrobial Resistance in the UK.

Cervical cancer kills over one third of a million women around the World every year. These deaths can be prevented through a program of vaccination and molecular diagnostic testing.

Canada is currently grappling with a severe shortage of skilled healthcare professionals, particularly in the fields of medical laboratory technology (MLT) and radiology technology (RT). Fast MDx's high-throughput testing can help to ease this situation.

A worryingly high number of cases are being confirmed by NHS England of Pertussis (Whooping Cough) in adolescents and adults, who usually suffer a milder form of the disease but with a cough that may persist for many weeks, hence the nickname of the 100 day cough.

The vaccination programs in the UK for influenza appear to be having good effect this Winter season, with no hospital admissions across the UK for the last 14 days.

Fast MDx Ltd, a London-based social enterprise, believes that their innovative molecular diagnostics test platform, the NGX 124, will revolutionize the early detection and quarantining of highly infectious diseases to prevent the spread of pandemics in the future.

Fast MDx was delighted to read an item in Genome Web covering our system obtaining the CE-IVDR mark for a fully automated, high-throughput open molecular diagnostic test system called NGX 124.

LabMedica published an article about the Fast MDx Molecular Diagnostic Test System.

Fast MDx was delighted to read an excellent article in Genome Web by Justin Petrone, that explains how the platform is being validated by Public Health Wales, which will complete Fast MDx’s UKCA and CE-IVDr regulatory approvals program.